Yahoo Web Search

  1. Ads
    related to macular degeneration
  1. Yahoo Finance Results

  2. EYLEA is the market-leading vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration, macular

  3. The week has been pretty slow with key announcements including Allergan’s AGN job cut announcement and Pfizer’s PFE collaboration agreements with companies like Sangamo and Arvinas. Allergan ...

  4. The MAKO study evaluated the efficacy and safety of topically administered squalamine in combination with monthly Lucentis® injections for the treatment of wet age-related macular degeneration ...

  5. LumiThera a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will present ...

  6. Momenta & Mylan to Initiate Trial on Biosimilar of Eylea

    Zacks via Yahoo FinanceJan 04 13:35 PM

    The trial will be a randomized, double-blind, active-control, multi-center study in patients with diabetic macular edema to compare the safety, efficacy and immunogenicity of M710 with ...

  7. (FDA) to begin the clinical feasibility study for PRIMA, Pixium Vision’s new-generation miniaturized wireless photovoltaic sub-retinal implant, in patients with Atrophic Dry Age-related Macular ...

  8. Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial

    GlobeNewswire via Yahoo FinanceJan 03 10:30 AM

    Used in combination with a VEGF-A inhibitor, OPT-302 has the potential to improve clinical outcomes in DME patients. This multi-centre clinical trial to be conducted in the US and Australia ...

  9. The ophthalmology drugs market covers drugs that are used in the treatment of eye related diseases such as refractive errors, cataracts, glaucoma, conjunctivitis, retinal diseases, and macular ...

  10. REGENXBIO Provides Year-End 2017 Corporate Update

    GlobeNewswire via Yahoo FinanceJan 04 21:05 PM

    RGX-111 for the treatment of Mucopolysaccharidosis Type I (MPS I) -- Site activation is continuing in the Phase I clinical trial evaluating RGX-111 for the treatment of MPS I. -- Patient recruitment ...

  11. Fitzpatrick, Cella, Harper & Scinto Announces Two New Partners

    Business Wire via Yahoo FinanceJan 02 15:18 PM

    BUSINESS WIRE)-- Fitzpatrick, Cella, Harper & Scinto, one of the world’s leading intellectual property law firms, announced that, effective January 1, 2018, Christopher Gerson and Damien Dombrowski ...

  1. Ads
    related to macular degeneration
  2. See more ads for: